Drug Information

Drug General Information
Drug ID
D0IJ1D
Former ID
DIB000398
Drug Name
HuM-195-Bi-213
Synonyms
SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195
Indication Acute myeloid leukemia [ICD9: 205; ICD10:C92.0] Discontinued in Phase 1/2 [546496]
Company
PDL BioPharma Inc
Target and Pathway
Target(s) Myeloid cell surface antigen CD33 Target Info Inhibitor [531172]
KEGG Pathway Hematopoietic cell lineage
Reactome Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
References
Ref 546496Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008571)
Ref 531172Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res. 2010 Nov 1;16(21):5303-11.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.